Drake, M. T., Clarke, B. L., & Khosla, S. (2008). Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clinic Proceedings, 83(9), 1032–1045.

Article  CAS  PubMed  Google Scholar 

De Rosa, G., Misso, G., Salzano, G., & Caraglia, M. (2013). Bisphosphonates and cancer: What opportunities from nanotechnology? Journal of Drug Delivery, 2013, 637976. https://doi.org/10.1155/2013/637976(Epub 2013 Mar 4).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heymann, D. (2010). Bisphosphonates and bone diseases: Past, present and future. Current Pharmaceutical Design, 16(27), 2948–2949.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grey, A., & Reid, I. R. (2006). Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Therapeutics and Clinical Risk Management, 2(1), 77–86.

CAS  PubMed  PubMed Central  Google Scholar 

McGreevy, C., & Williams, D. (2011). Safety of drugs used in the treatment of osteoporosis. Therapeutic Advances in Drug Safety, 2(4), 159–172.

Article  PubMed  PubMed Central  Google Scholar 

Cremers, S., & Papapoulos, S. (2011). Pharmacology of bisphosphonates. Bone, 49(1), 42.

Article  CAS  PubMed  Google Scholar 

Bhadada, S. K., Chadha, M., Sriram, U., Pal, R., Paul, T. V., Khadgawat, R., et al. (2021). The Indian Society for Bone and Mineral Research (ISBMR) position statement for the diagnosis and treatment of osteoporosis in adults. Archives of Osteoporosis, 16(1), 102.

Article  PubMed  Google Scholar 

Boivin, G. Y., Chavassieux, P. M., Santora, A. C., Yates, J., & Meunier, P. J. (2000). Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone, 27(5), 687–694.

Article  CAS  PubMed  Google Scholar 

McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., et al. (2001). Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New England Journal of Medicine, 344(5), 333–340.

Article  CAS  PubMed  Google Scholar 

Cummings, S. R., Black, D. M., Thompson, D. E., et al. (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA, 280(24), 2077–2082.

Article  CAS  PubMed  Google Scholar 

Harris, S. T., Watts, N. B., Genant, H. K., et al. (1999). Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA, 282(14), 1344–1352.

Article  CAS  PubMed  Google Scholar 

Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., et al. (1996). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet, 348(9041), 1535–1541.

Article  CAS  PubMed  Google Scholar 

Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., et al. (2004). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research., 19(8), 1241–1249.

Article  CAS  PubMed  Google Scholar 

Delmas, P. D., Recker, R. R., Chesnut, C. H., Skag, A., Stakkestad, J. A., Emkey, R., et al. (2004). Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteoporosis International, 15(10), 792–798.

Article  CAS  PubMed  Google Scholar 

Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., et al. (2007). HORIZON Pivotal Fracture. Trial once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine, 356(18), 1809–1822.

Article  CAS  PubMed  Google Scholar 

Greenspan, S. L., Emkey, R. D., Bone, H. G., Weiss, S. R., Bell, N. H., Downs, R. W., et al. (2002). Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine, 137(11), 875–883.

Article  CAS  PubMed  Google Scholar 

Compston, J. E., & Watts, N. B. (2002). Combination therapy for postmenopausal osteoporosis. Clinical Endocrinology - Oxford, 56(5), 565–569.

Article  CAS  PubMed  Google Scholar 

Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., et al. (2003). PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New England Journal of Medicine, 349(13), 1207–1215.

Article  CAS  PubMed  Google Scholar 

Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., & Neer, R. M. (2003). The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. New England Journal of Medicine, 349(13), 1216–1226.

Article  CAS  PubMed  Google Scholar 

Buckley, L., Guyatt, G., Fink, H. A., Cannon, M., Grossman, J., Hansen, K. E., et al. (2017). 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis and Rheumatology., 69(8), 1521–1537.

Article  PubMed  Google Scholar 

Whyte, M. P. (2006). Clinical practice. Paget’s disease of bone. The New England Journal of Medicine, 355(6), 593–600.

Article  CAS  PubMed  Google Scholar 

Bhadada, S., Bhansali, A., Unnikrishnan, A. G., Khadgawat, R., Singh, S. K., Mithal, A., & Saikia, U. N. (2006). Does Paget’s disease exist in India? A series of 21 patients. Journal of the Association of Physicians of India, 54, 530–534.

CAS  PubMed  Google Scholar 

Siris, E. S. (1994). Perspectives: A practical guide to the use of pamidronate in the treatment of Paget’s disease. Journal of Bone and Mineral Research, 9(3), 303–304.

Article  CAS  PubMed  Google Scholar 

Bhadada, S. K., Pal, R., Sood, A., Dhiman, V., & Saini, U. C. (2019). Co-administration of systemic and intralesional zoledronic acid in a case of fibrous dysplasia: A potentially novel therapy. Frontiers in Endocrinology (Lausanne), 19(10), 803. https://doi.org/10.3389/fendo.2019.00803(PMID: 31803145; PMCID: PMC6877477)

Article  Google Scholar 

Lewiecki, E. M. (2010). Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. Core Evidence, 15(4), 13–23.

Google Scholar 

de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996). Esophagitis associated with the use of alendronate. New England Journal of Medicine, 335(14), 1016–1021.

Article  PubMed  Google Scholar 

Kennel, K. A., & Drake, M. T. (2009). Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clinic Proceedings, 84(7), 632–637.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Do, W. S., Park, J. K., Park, M. I., Kim, H. S., Kim, S. H., & Lee, D. H. (2012). Bisphosphonate-induced severe hypocalcemia—a case report. Journal of Bone and Metabolism, 19(2), 139–145.

Article  Google Scholar 

Noriega Aldave, A. P., & Jaiswal, S. (2014). Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: A case report. Journal of Medical Case Reports, 23(8), 353.

Article  Google Scholar 

Majumdar, S. R. (2008). Oral bisphosphonates and atrial fibrillation. BMJ, 336(7648), 784–785.

Article  PubMed  PubMed Central  Google Scholar 

Rastogi, A., Rattan, V., & Bhadada, S. K. (2012). Osteonecrosis of jaw associated with bisphosphonate use. Indian Journal of Endocrinology and Metabolism, 16(3), 450–452. https://doi.org/10.4103/2230-8210.95711(PMID: 22629519; PMCID: PMC3354860).

Article  PubMed  PubMed Central  Google Scholar 

Xiao, Y., Chen, Y., Huang, Y., & Xiao, Y. (2023). Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. Science and Reports, 13(1), 10892.

Article  CAS  Google Scholar 

Bhadada, S. K., Sridhar, S., Muthukrishnan, J., Mithal, A., Sharma, D. C., Bhansali, A., & Dhiman, V. (2014). Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature. Indian Journal of Medical Research, 140(1), 46–54 (PMID: 25222777; PMCID: PMC4181159.A1).

CAS  PubMed  PubMed Central  Google Scholar 

Zhang, C., & Song, C. (2021). Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives. Frontiers in Pharmacology, 27(11), 607017.

Article  Google Scholar 

Diab, D. L., & Watts, N. B. (2013). Bisphosphonate drug holiday: Who, when and how long. Therapeutic Advances in Musculoskeletal Disease, 5(3), 107–111.

Article  CAS  PubMed  PubMed Central  Google Scholar